Acknowledgements
This study was performed with the assistance of the Princess Margaret Leukemia Tissue Bank and the Elizabeth and Tony Comper Foundation to the MPN Program at the Princess Margaret Cancer Centre (V.G.).
Author contributions
The study was conceived by AGH and TM. AGH abstracted, collected, and analyzed the data. DM, CJM, HS, VG, and TM provided study patients. AGH and TM drafted the manuscript. All authors reviewed and approved the final version of the manuscript.
Disclosure statement
VG has served on the advisory board of Novartis, Celgene, Pfizer, and Sierra Oncology; received research funding from Novartis and Incyte. TM has served on advisory boards for Trillium Therapeutics. All other authors do not have conflicts of interest to declare.